Depending on which GPIIbIIIa is used, Angiomax alone can still be more expensive. And some Angiomax patients also get a GPIIbIIIa, in which case the comparison boils down to Angiomax vs heparin.
Suppose for the sake of argument that all anticoagulant and antiplatelet drugs used in a hospital setting were free. Would the market share of Angiomax in this setting go up? I think the answer is obvious.
News 
Market Data 
Discover 
